

BMJ Open The Optimal Screening for Prediction of Referral and Outcome (OSPRO) in patients with musculoskeletal pain conditions: a longitudinal validation cohort from the USA

Steven Z George,^{1,2} Jason M Beneciuk,³ Trevor A Lentz,⁴ Samuel S Wu⁵

To cite: George SZ, Beneciuk JM, Lentz TA, *et al.* The Optimal Screening for Prediction of Referral and Outcome (OSPRO) in patients with musculoskeletal pain conditions: a longitudinal validation cohort from the USA. *BMJ Open* 2017;7:e015188. doi:10.1136/bmjopen-2016-015188

Received 14 November 2016
Revised 5 April 2017
Accepted 27 April 2017



CrossMark

¹Musculoskeletal Research, Duke Clinical Research Institute, Durham, North Carolina, USA

²Orthopaedic Surgery, Duke University, Durham, North Carolina, USA

³Department of Physical Therapy, Brooks—PHEP Research Collaboration, University of Florida, Gainesville, Florida, USA

⁴Department of Physical Therapy, University of Florida, Gainesville, Florida, USA

⁵Department of Biostatistics, University of Florida, Gainesville, Florida, USA

Correspondence to

Dr Steven Z George;
steven.george@duke.edu

ABSTRACT

Purpose There is an increased need for determining which patients with musculoskeletal pain benefit from additional diagnostic testing or psychologically informed intervention. The Optimal Screening for Prediction of Referral and Outcome (OSPRO) cohort studies were designed to develop and validate standard assessment tools for review of systems and yellow flags. This cohort profile paper provides a description of and future plans for the validation cohort.

Participants Patients (n=440) with primary complaint of spine, shoulder or knee pain were recruited into the OSPRO validation cohort via a national Orthopaedic Physical Therapy Investigative Network. Patients were followed up at 4 weeks, 6 months and 12 months for pain, functional status and quality of life outcomes. Healthcare utilisation outcomes were also collected at 6 and 12 months.

Findings to date There are no longitudinal findings reported to date from the ongoing OSPRO validation cohort. The previously completed cross-sectional OSPRO development cohort yielded two assessment tools that were investigated in the validation cohort.

Future plans Follow-up data collection was completed in January 2017. Primary analyses will investigate how accurately the OSPRO review of systems and yellow flag tools predict 12-month pain, functional status, quality of life and healthcare utilisation outcomes. Planned secondary analyses include prediction of pain interference and/or development of chronic pain, investigation of treatment expectation on patient outcomes and analysis of patient satisfaction following an episode of physical therapy.

Trial registration number The OSPRO validation cohort was not registered.

INTRODUCTION

In USA, interest in direct access physical therapy is increasing because it has been associated with lower cost, less healthcare utilisation and higher patient satisfaction.^{1,2} Currently, all 50 states, the District of Columbia and the US Virgin Islands allow patients to seek some level

of treatment from a licensed physical therapist without a prescription or referral from a physician³; however, medical and chiropractic organisations have questioned whether physical therapists should be front line providers for patients with musculoskeletal pain.⁴

One high priority area for allaying these concerns is the development of standard processes that aid in determining suitability for individuals seeking their care. Review of systems of the body is a routine examination process with the goal of identifying concomitant disease suggesting a non-musculoskeletal cause of pain.⁵ This process typically involves a symptom review followed by focused physical examination as appropriate. During review of systems of the body, attention is paid to whether referral for additional diagnostic testing is required. Another high priority area for developing standard assessment processes is the identification of pain-associated psychological distress (ie, 'yellow flags'). Yellow flags are psychological prognostic factors for the development of disability following the onset of musculoskeletal pain.⁶ In extreme cases, psychological distress could necessitate referral to another provider, but more commonly pain-associated psychological distress is a precursor of delayed recovery and indicates the need for psychologically informed interventions.⁷

There are barriers to consistently performing review of systems and identifying pain-associated psychological distress. Review of systems involves querying the presence of 'red flag' symptoms. The variability of red flag symptom descriptors used and their lack of accuracy in predicting systemic involvement limit the implementation of standard, evidence-supported approaches for review of symptoms linked directly to identification of

serious pathology.^{8–10} Instead, alternative approaches to red flag screening in the form of identifying predictors of comorbidity status change have shown promise for improving patient management strategies but require further study.¹¹ Furthermore, literature support for the predictive value of identifying pain associated psychological distress, or yellow flags, has not led to this type of assessment being common in physical therapy practice. The lack of psychological assessment in physical therapy practice is likely due to it not being taught in educational settings and the large number of potential psychological factors to monitor creates confusion over which best drives clinical decision making.^{6 12 13}

Physical therapists currently make clinical decisions for review of systems and identification of pain-associated psychological distress without standard assessment tools and processes.^{10 14} Therefore, clinical decisions made by physical therapists could be an important contributor to suboptimal outcomes and/or excessive healthcare cost or utilisation. There are successful models for standard, concise assessment processes. For example, the Ottawa Ankle Rules accurately determine which patients are appropriate for radiographic testing.¹⁵ Physical therapists would benefit from similar processes to enhance clinical decision making for patients across common musculoskeletal pain conditions. In particular, our efforts were focused on developing and validating tools that (1) facilitated review of symptoms for predicting change in comorbidity status and (2) identified relevant aspects of pain-associated psychological distress for predicting poor clinical outcomes for pain and functional status.

These tools were developed with the support of the Orthopaedic Section of the American Physical Therapy Association. Their Clinical Research Network funding mechanism supported the Orthopaedic Physical Therapy-Investigator Network (OPT-IN) to complete the Optimal Screening for Prediction of Referral and Outcome (OSPRO) separate development and validation cohort studies. The completed development cohort study involved the creation and initial psychometric testing of the OSPRO-Review of Systems (OSPRO-ROS) and OSPRO-Yellow Flag (OSPRO-YF) screening tools. The validation cohort study involves administering the newly developed OSPRO-ROS and OSPRO-YF tools to determine their predictive validity for clinical outcomes, comorbidity change and healthcare utilisation. The purpose of this manuscript is to provide an overview of the OSPRO validation cohort study design and methodology as well as define the baseline status of the cohort and indicate future plans for validation analyses. Our overall intent was to provide some transparency before results are reported by providing a detailed description of the methods and indicate our planned analyses prior to completing final follow-up for the cohort.

COHORT DESCRIPTION

Overview

A convenience sample was gathered from December 2014 and December 2015 by participating OPT-IN clinics. Physical therapists practising in these clinics determined participant eligibility at initial evaluation. Baseline and follow-up data collection occurred online, with participants completing all survey assessments on the study website. Follow-up time points were at 4 weeks, 6 months and 12 months and participants were notified of a pending assessment by an email that directed them back to the study website to complete their follow-up assessment. If participants did not complete their follow-up assessment within 1 week of the first email notification, an additional email reminder was sent each week for up to 3 weeks. Participants who were not responsive to any of these email reminders were contacted by telephone. Follow-up for the validation cohort is on-going and was completed in January 2017 (figure 1).

Clinical sites

OPT-IN clinical sites (n=9) were identified through various methods that included advertisement by the Orthopaedic Section, previous collaborative relationships, geographic location, type of setting and suggestions from the Section's advisory board. Clinics that were able to commit to recruiting 50 subjects and agreed to complete training were included in the network. Clinical sites were contacted by study investigators to discuss recruitment expectations and training procedures. Clinic training was performed on-site (n=3) or via videoconference (n=6) and included modules on study background, eligibility criteria and subject recruitment strategies.

The OPT-IN clinics that participated in data collection represented five of eight geographic regions for USA including the Mideast, Southeast, Great Lakes, Rocky Mountain States and Far West. The New England, Plains and Southwest regions were not represented. An attempt was made to balance between urban and rural settings over the entire OPT-IN network, though for pragmatic reasons that balance was not provided within each geographic region.

Participants

The OSPRO validation cohort study was approved by the University of Florida Human Subjects Institutional Review Board and all participants provided consent to participate in the study.

Eligible participants were directed to a secure, University of Florida hosted website for the informed consent process and baseline assessment. All assessments were self-report and completed electronically by the participant in a de-identified manner. Eligibility criteria were reviewed by licensed physical therapists employed within an OPT-IN clinical site. Criteria were intentionally broad since our intent was to develop assessment tools with potentially wide clinical application. Using narrow eligibility criteria would have excluded a significant number




Figure 1 Study flow diagram for OSPRO validation study. *Items in bold are planned primary outcomes. OSPRO, Optimal Screening for Prediction of Referral and Outcome.

of patients commonly seen by orthopaedic physical therapists, resulting in limited application of these tools. The same eligibility criteria were used for the development and validation cohorts. Demographic and clinical summary of the validation cohort is reported in [table 1](#).

Inclusion criteria

Patients between the ages of 18 and 65 years of age were eligible to participate in this study if they: (1) were seeking outpatient physical therapy treatment for musculoskeletal pain, (2) had primary complaints involving the cervical spine, lumbar spine, shoulder or knee and (3) were able to read and comprehend English language (this criterion was necessary due to the large number of self-report forms used at intake and follow-up).

Exclusion criteria

Patients were excluded from study participation for any diagnosis indicative of (1) widespread chronic pain syndrome (eg, fibromyalgia or irritable bowel syndrome), (2) neuropathic pain syndrome (eg, complex regional pain syndrome or diabetic neuropathy), (3) psychiatric

history (currently in care of mental healthcare provider or taking ≥ 2 prescription psychiatric medications), (4) cancer (currently receiving treatment for active cancer) and (5) neurological disorder (eg, stroke, spinal cord injury or traumatic brain injury).

Predictive measures

Predictive measures were collected during the initial session, either while in the clinic or at home after the session. Subjects who preferred to complete the survey at home were provided a handout with a link to the study website. OSPRO validation cohort baseline values for key predictive measures are reported in [table 2](#).

Demographic and historical information

Participants completed a standard intake form previously used in our clinical studies including age, sex, race, ethnicity, employment status, litigation status, marital status, educational level, insurance provider type, self-reported health status and surgical history.¹⁶⁻¹⁸ Historical data included anatomical location of the pain, onset of symptoms, duration of symptoms, previous episodes and previous treatments.

Table 1 Baseline description of key demographic and historical variables for OSPRO validation cohort

Variable	Label	Overall (n=440)	Neck (n=98)	Low back (n=118)	Shoulder (n=107)	Knee (n=117)
Age* (2 missing)	Mean ±SD	45.2±15.8	42.8±14.7	45.6±16.0	47.8±16.0	44.5±16.2
	Median (Min, Max)	45 (18, 75)	41 (20, 74)	45 (18, 75)	51 (18, 73)	44.5 (18, 75)
Gender	Male	164 (37.3%)	23 (23.5%)	49 (41.5%)	50 (46.7%)	42 (35.9%)
	Female	275 (62.5%)	74 (75.5%)	69 (58.5%)	57 (53.3%)	75 (64.1%)
	Not answered	1 (0.2%)	1 (1.0%)			
Race	American Indian/ Alaska Native	3 (0.7%)	1 (1.0%)	1 (0.8%)	1 (0.9%)	
	Asian	25 (5.7%)	5 (5.1%)	1 (0.8%)	9 (8.4%)	10 (8.5%)
	Black or African American	62 (14.1%)	13 (13.3%)	15 (12.7%)	11 (10.3%)	23 (19.7%)
	White	343 (78.0%)	75 (76.5%)	100 (84.7%)	86 (80.4%)	82 (70.1%)
	Not answered	7 (1.6%)	4 (4.1%)	1 (0.8%)		2 (1.7%)
Ethnicity	Hispanic or Latino	31 (7.0%)	9 (9.2%)	7 (5.9%)	7 (6.5%)	8 (6.8%)
	Not Hispanic or Latino	376 (85.5%)	81 (82.7%)	101 (85.6%)	97 (90.7%)	97 (82.9%)
	Not answered	33 (7.5%)	8 (8.2%)	10 (8.5%)	3 (2.8%)	12 (10.3%)
Income	Less than \$200 000	59 (13.4%)	7 (7.1%)	18 (15.3%)	16 (15.0%)	18 (15.4%)
	\$20 000–\$35 000	53 (12.0%)	15 (15.3%)	16 (13.6%)	8 (7.5%)	14 (12.0%)
	\$35 001–\$50 000	50 (11.4%)	14 (14.3%)	10 (8.5%)	7 (6.5%)	19 (16.2%)
	\$50 001–\$70 000	56 (12.7%)	19 (19.4%)	15 (12.7%)	11 (10.3%)	11 (9.4%)
	Greater than \$70 000	156 (35.5%)	27 (27.6%)	41 (34.7%)	50 (46.7%)	38 (32.5%)
Not answered	66 (15.0%)	16 (16.3%)	18 (15.3%)	15 (14.0%)	17 (14.5%)	
Employed	Full-time	237 (53.9%)	66 (67.3%)	52 (44.1%)	58 (54.2%)	61 (52.1%)
	Part-time	62 (14.1%)	13 (13.3%)	21 (17.8%)	18 (16.8%)	10 (8.5%)
	Unemployed	61 (13.9%)	8 (8.2%)	20 (16.9%)	12 (11.2%)	21 (17.9%)
	Retired	58 (13.2%)	7 (7.1%)	21 (17.8%)	14 (13.1%)	16 (13.7%)
	Not answered	22 (5.0%)	4 (4.1%)	4 (3.4%)	5 (4.7%)	9 (7.7%)

Continued

Table 1 Continued

Variable	Label	Overall (n=440)	Neck (n=98)	Low back (n=118)	Shoulder (n=107)	Knee (n=117)
Education	Less than high school	11 (2.5%)	2 (2.0%)	4 (3.4%)	1 (0.9%)	4 (3.4%)
	Graduated from high school	38 (8.6%)	3 (3.1%)	13 (11.0%)	12 (11.2%)	10 (8.5%)
	Some college	112 (25.5%)	24 (24.5%)	34 (28.8%)	25 (23.4%)	29 (24.8%)
	Graduated from college	120 (27.3%)	33 (33.7%)	31 (26.3%)	30 (28.0%)	26 (22.2%)
	Some postgraduate	56 (12.7%)	12 (12.2%)	13 (11.0%)	12 (11.2%)	19 (16.2%)
Insurance	Completed postgraduate	97 (22.0%)	20 (20.4%)	22 (18.6%)	26 (24.3%)	29 (24.8%)
	Not answered	6 (1.4%)	4 (4.1%)	1 (0.8%)	1 (0.9%)	
	Private	273 (62.0%)	65 (66.3%)	74 (62.7%)	62 (57.9%)	72 (61.5%)
	Medicare	52 (11.8%)	4 (4.1%)	17 (14.4%)	12 (11.2%)	19 (16.2%)
	Medicaid	19 (4.3%)	5 (5.1%)	7 (5.9%)	4 (3.7%)	3 (2.6%)
Onset of symptoms	Worker's compensation	14 (3.2%)	5 (5.1%)	4 (3.4%)	4 (3.7%)	1 (0.9%)
	Disability	4 (0.9%)		1 (0.8%)	1 (0.9%)	2 (1.7%)
	Uninsured	7 (1.6%)	2 (2.0%)	1 (0.8%)	3 (2.8%)	1 (0.9%)
	Other	45 (10.2%)	10 (10.2%)	12 (10.2%)	10 (9.3%)	13 (11.1%)
	Not answered	26 (5.9%)	7 (7.1%)	2 (1.7%)	11 (10.3%)	6 (5.1%)
Previous episodes over past year	Gradual	239 (54.3%)	51 (52.0%)	61 (51.7%)	54 (50.5%)	73 (62.4%)
	Sudden	138 (31.4%)	34 (34.7%)	47 (39.8%)	31 (29.0%)	26 (22.2%)
	Traumatic	63 (14.3%)	13 (13.3%)	10 (8.5%)	22 (20.6%)	18 (15.4%)
Work-related	Yes	224 (50.9%)	43 (43.9%)	68 (57.6%)	57 (53.3%)	56 (47.9%)
	No	185 (42.0%)	43 (43.9%)	43 (36.4%)	44 (41.1%)	55 (47.0%)
	Do not remember	31 (7.0%)	12 (12.2%)	7 (5.9%)	6 (5.6%)	6 (5.1%)
Surgery for primary complaint	Yes	63 (14.3%)	19 (19.4%)	19 (16.1%)	15 (14.0%)	10 (8.5%)
	No	345 (78.4%)	68 (69.4%)	94 (79.7%)	83 (77.6%)	100 (85.5%)
	Not answered	32 (7.3%)	11 (11.2%)	5 (4.2%)	9 (8.4%)	7 (6.0%)
Surgery for primary complaint	Yes	83 (18.9%)	5 (5.1%)	13 (11.0%)	24 (22.4%)	41 (35.0%)
	No	357 (81.1%)	93 (94.9%)	105 (89.0%)	83 (77.6%)	76 (65.0%)

*Indicates missing items with number of subjects for a given variable reported in column.

Table 2 Baseline description of key predictors for OSPRO validation cohort

Variable	Label	Overall (n=440)	Neck (n=98)	Low back (n=118)	Shoulder (n=107)	Knee (n=117)
Composite number of comorbidities	Mean±SD	2.0±2.2	1.9±1.8	2.5±2.4	1.6±2.0	2.0±2.2
	Median (min, max)	1 (0, 12)	2 (0, 6)	2 (0, 10)	1 (0, 12)	1 (0, 10)
Distribution of number of comorbidities	0	139 (31.6%)	33 (33.7%)	26 (22.0%)	38 (35.5%)	42 (35.9%)
	1	85 (19.3%)	13 (13.3%)	26 (22.0%)	23 (21.5%)	23 (19.7%)
	2 +	216 (49.1%)	52 (53.1%)	66 (55.9%)	46 (43.0%)	52 (44.4%)
OSPRO-ROS (1–10)	Mean±SD	2.7±2.4	3.8±2.2	2.4±2.1	2.5±2.6	2.2±2.3
	Median (min, max)	2 (0, 10)	4 (0, 9)	2 (0, 8)	2 (0, 10)	1 (0, 10)
OSPRO-ROS (11–23)	Mean±SD	1.2±1.8	1.5±2.0	1.2±1.6	1.1±1.9	1.2±1.7
	Median (min, max)	1 (0, 12)	1 (0, 9)	1 (0, 9)	0 (0, 12)	0 (0, 7)
OSPRO-YF (1–10)	Mean±SD	17.4±6.7	17.2±7.0	17.7±7.1	17.5±6.4	17.3±6.3
	Median (min, max)	17 (4, 47)	17 (4, 40)	16.5 (5, 47)	17 (4, 36)	17 (4, 36)
OSPRO-YF (11–17)	Mean±SD	14.9±5.5	14.8±5.8	14.9±5.6	15.3±5.4	14.7±5.4
	Median (min, max)	15 (3, 34)	14 (3, 30)	15 (4, 34)	15 (4, 32)	15 (3, 27)

Composite and distribution number of comorbidities derived from unique responses to Charlson and Functional Comorbidity Indices. OSPRO-ROS, OSPRO Review of Systems Tool; OSPRO-YF, OSPRO Yellow Flag tool.

Comorbidities

Health history was determined with the Charlson and Functional Comorbidity Indices.^{19 20} The Charlson Comorbidity Index lists 19 medical conditions that participants are asked to indicate whether they 'have ever been diagnosed with by a physician'. Similarly, the Functional Comorbidity Index lists 18 medical conditions that participants are asked to indicate whether they 'have ever been diagnosed with by a physician'. These indices were selected because they assess different medical conditions and inclusion of both would allow for full consideration of comorbidities. A composite comorbidity count was derived by adding unique number of comorbidities reported in the Charlson and Functional Comorbidity Indices (ie, similar comorbidities reported in both indices were only counted once).

Review of systems

The OSPRO-ROS tool²¹ was administered at baseline. This measure includes standard symptom descriptors used in the past to aid with identification of systemic involvement. It includes questions related to symptoms of the cardiovascular, gastrointestinal, endocrine, nervous, integumentary, pulmonary and musculoskeletal systems. In the OSPRO validation cohort, the 10-item and 23-item versions of the OSPRO-ROS tool will be considered in predictive analyses.²¹

Yellow flags

The OSPRO-YF tool²² was also administered at baseline. This measure includes items from pain vulnerability domains (negative affect and fear-avoidance) and pain resilience domains (positive affect and self-efficacy) to aid with identification of pain associated psychological distress.²² In the OSPRO validation cohort, the 17-item and 10-item versions of the OSPRO-YF tool will be considered in predictive analyses.

Intervention

All physical therapy treatment was provided at the discretion of the treating clinician. The duration of the episode, the number of physical therapy visits and individual treatment parameters (type, intensity, duration, frequency) were not collected.

Outcome measures

A tiered approach was used for outcome assessment consisting of initial contact by email for online data collection and then telephone follow-up for those who were not responsive to email. The telephone follow-up was used to guide the participant back to the secured web collection or the option for the participant to provide data over the phone for entry by one of the study investigators.

Primary and secondary measures were collected to determine whether there were any important status changes in health for longer-term outcomes. At 4 weeks, primary outcome assessment included pain intensity and self-report functional status to capture information about immediate response to the physical therapy episode. At 6 and 12 months, primary outcome assessment includes

pain intensity and functional measures as well as previously mentioned comorbidity assessment. Measures of chronic pain development or maintenance, healthcare utilisation, treatment expectations and patient satisfaction were collected at 6 and 12 months as secondary outcomes. OSPRO validation cohort baseline values for outcome measures are reported in [table 3](#). These outcome measures are described in more detail below.

Pain intensity

Pain intensity was assessed by the Numeric Rating Scale ranging from '0' (no pain) to '10' (worst pain imaginable).²³⁻²⁵ Participants rated their current pain intensity as well as their best (lowest) and worst (highest) pain intensity over the past 24 hours.

Pain interference

Pain interference was assessed with four questions to determine the extent to which pain interfered with the participant's abilities to participate in (1) daily activities, (2) work around the home, (3) social activities and (4) household chores over the previous 7 days. Potential responses were 'None at all', 'A little bit', 'Somewhat', 'Quite a bit' and 'Very much'.

Self-report of functional status

Self-report of functional status was assessed at intake and 1-year follow-up with two measures: (1) the Medical Outcomes Study 8-item Short-Form Health Survey (SF-8), which is a general quality of life measure that has physical and mental health domains²⁶ and (2) the Neck Disability Index (NDI),²⁷⁻²⁸ Oswestry Disability Questionnaire,²⁹⁻³⁰ Quick Disability of Arm, Shoulder and Hand (DASH)³¹ or International Knee Documentation Committee Subjective Knee Form³² as condition specific measures for cervical, low back, shoulder and knee pain, respectively.

Persistent or chronic pain status

Persistent or chronic pain status was assessed by self-report responses to questions accounting for duration of pain and activity limitations. At intake, pain status was determined using established definitions that account for the duration of pain and activity limitations³³⁻³⁴ using the following two questions: (1) 'How long have you been experiencing your current painful symptoms?' and (2) 'Have you experienced ANY pain and activity limitations everyday for the past 3 months?' For 6-month and 12-month follow-up assessments, we included questions to assess: (1) duration of symptoms over follow-up time and (2) duration of persistent, ongoing symptoms over consecutive days. These questions were selected as they were similar to what was done for defining chronic low back pain.³⁵

Healthcare utilisation

Healthcare utilisation was assessed with questions derived from previous population-based studies involving musculoskeletal pain that have used survey methods for follow-up assessment.³³⁻³⁴ Briefly, patients were asked whether they have used any of the following: prescription pain medication, injection, imaging, surgery, emergency room visits.

'Yes' responses were followed by questions regarding number of visits, types of diagnostic tests performed and interventions received. At 6 months, patients were queried about their utilisation over the past 2 months, allowing for a 4-month window for the current treatment episode to not be accounted for in this assessment. At 12 months, patients were queried about their utilisation over the past 6 months.

Treatment expectation

Treatment expectation was assessed at 6 and 12 months with one item asking patients 'Are the results of your physical therapy treatment what you expected?' (1—'definitely not' to 5—'definitely yes').³⁶⁻³⁷

Patient satisfaction

Patient satisfaction was assessed at 6 and 12 months with three separate items asking patients: (1) 'If you had to spend the rest of your life with the symptoms you have right now, how would you feel about it?' (1—'very dissatisfied' to 5—'very satisfied'), (2) 'Would you have the same physical therapy treatment again if you had the same condition?' (1—'definitely not' to 5—'definitely yes') and (3) 'How would you rate the overall results of your physical therapy treatment?' (1—'terrible' to 6—'excellent').³⁶⁻³⁷

Power analysis

Sample size estimates were based on precision for the assessment tools. The sample size was calculated so that 95% CI for the accuracy of predicting 23-item versions of the OSPRO-ROS tool from the abbreviated 10-item version have a width of at most $\pm 5\%$. Specifically, we required that sample size N satisfies $\sqrt{p^*(1-p)/N} * 1.96 < 0.05$, where p is the prediction accuracy. This calculation yielded 385 patients with neck, shoulder, low back or knee pain. A liberal estimate of 20% loss to follow-up at 1 year results in a required total sample size of 462, or approximately 115 patients for each anatomical region.

Overview of analysis plan

The analysis plan was first developed in 2012 as part of the original grant proposal, with only minor modifications made for changing specific measures during study implementation. Our primary analyses will assess the accuracy of predicting 12-month clinical and healthcare utilisation outcomes by the newly developed assessment tools. The outcomes of pain intensity (numeric pain rating scale (NPRS)), condition specific function (z transformed scores for NDI, ODI, DASH and lower extremity function scale (LEFS)), quality of life (SF-8) and comorbidity change (from Charlson and/or Functional Comorbidity indices) will be fitted with generalised linear models using the newly developed screening tools as planned fixed effects. Logistic regression models will be fitted for dichotomous outcomes on various parameters of healthcare utilisation (eg, opioid use, injection, imaging, surgery and/or ER visits). We will consider age, sex, region of pain, clinical site, socioeconomic status, comorbidities (from Charlson and/or Functional Comorbidity

Table 3 Baseline description of key outcome variables for the OSPRO validation cohort

Variable	Label	Overall (n=440)	Neck (n=98)	Low back (n=118)	Shoulder (n=107)	Knee (n=117)
SF-8 Physical Component (0–100)	Mean ±SD	42.7±8.5	43.8±7.5	40.9±7.8	44.7±8.6	41.8±9.3
	Median (min, max)	43.7 (22.4, 59)	44.6 (25.5, 58.2)	40.1 (25.6, 57.8)	46.8 (25.3, 58.4)	42.5 (22.4, 59)
SF-8 Mental Component (0–100)	Mean±SD	50.9±9.1	49.0±9.2	50.4±8.9	51.1±9.4	53.0±8.6
	Median (min, max)	53 (22.6, 68.8)	51.2 (26, 62)	51.8 (27.7, 63.7)	53.8 (22.6, 64.7)	55.2 (26.8, 68.8)
Pain Intensity (0–10 NRS)	Mean±SD	4.2±2.0	4.3±1.9	4.5±1.7	4.1±2.1	4.0±2.2
	Median (min, max)	4 (0, 9.7)	4.3 (0, 9)	4.3 (0.7, 9.7)	4 (0.3, 9.3)	3.7 (0, 9)
Neck Disability Index (%)	Mean±SD		28.6±16.1			
	Median (min, max)		24 (2, 76)			
Oswestry Disability Index (%)	Mean±SD			28.7±18.2		
	Median (min, max)			26 (0, 86)		
Quick-DASH Score (0–100)	Mean±SD				38.8±20.1	
	Median (min, max)				34.1 (2.3, 97.7)	
IKDC Score* (0–100) (16 missing)	Mean±SD					39.6±15.7
	Median (min, max)					39.2 (7.2, 77.3)

*Indicates missing items with number of subjects for a given variable reported in column.

DASH, Disability of Arm, Shoulder, Hand questionnaire; IKDC, International Knee Documentation Committee Subjective Evaluation Form; NRS, Numeric Rating Scale.

indices) and corresponding outcome measure at baseline as *planned* covariates in all prediction models.

Primary analyses will first be conducted with missing 12-month outcomes imputed by last-value-carried-forward method. The results will be compared with those obtained from complete case only analysis and those obtained from multiple imputations. Planned secondary analyses include prediction of other 12-month outcomes including pain interference, development of chronic pain, treatment expectation and patient satisfaction.

FINDINGS TO DATE

There are no longitudinal findings reported to date from the on-going OSPRO validation cohort. The separate and completed cross-sectional OSPRO development cohort yielded two assessment tools, the OSPRO-ROS²¹ and OSPRO-YF²², which serve as the primary predictors for the validation cohort.

Briefly, the OSPRO-ROS tool included items that accurately identified patients responding positively to at least one of the 97 items in a red flag symptom item bank. In psychometric analyses, a 10-item version of the OSPRO-ROS tool identified 94.7% of the positive responders to at least one of the items. A 23-item version of the OSPRO-ROS tool provided 100% accuracy. The OSPRO-ROS tools and the complete 97-item bank had similar correlations with concurrent clinical measures, except for a weaker association with depressive symptoms for the OSPRO-ROS tools. However, the ROS tools did still have a moderate positive association with depressive symptoms.

The OSPRO-YF tool included items that estimated established measures of pain vulnerability (negative affect and fear-avoidance) and resilience (positive affect and self-efficacy). In psychometric analyses, the 17-item version of the OSPRO-YF tool identified elevated vulnerability and decreased resilience with at least 85% accuracy. A 10-item and 7-item version of the OSPRO-YF tool provided at least 81% and 75% accuracy, respectively. All versions of the OSPRO-YF tool contributed additional variance in multivariate analyses investigating associations with measures of pain and disability (ranging from 19.3% to 36.7%) after controlling for demographics, historical variables and anatomical region of pain. These tools are described in much more detail in the original papers.^{21 22}

STRENGTHS AND LIMITATIONS

The primary strength of the OSPRO validation cohort is the planned methodology to evaluate prognostic capabilities of newly developed assessment tools specifically designed to be concise and useful for clinical decision making. Another strength of this cohort is that patient follow-up occurred at 12 months following an initial physical therapy encounter and included a wide variety of outcomes. Finally, a strength of this cohort study is use of assessment tools with flexibility for routine administration

in busy practice settings. We acknowledge simply developing and validating assessment tools does not guarantee a shift in clinical practice but it is a strength that these assessment tools can be administered using classical pen and paper methods. However, ideally they would be implemented and scored electronically to limit clinician burden. This is particularly important for the OSPRO-YF tool which has complicated scoring algorithms to provide score estimates of established full-length questionnaires. Electronic implementation will also allow for development of computer-based decision support systems, such as has been done for risk assessment involving worker's compensation^{38 39} and chronic low back pain.⁴⁰

The primary limitation of the OSPRO validation cohort is the reliance on convenience sampling for recruitment for pragmatic reasons. It would have been too burdensome for participating clinics to consecutively track patients for enrolment in the study. Concerns about selection bias are somewhat mitigated by our intentionally broad eligibility criteria that resulted in similarities in many demographic and clinical variables between the development and validation cohorts. However, because the OSPRO-ROS and OSPRO-YF tools are newly developed, data are lacking to compare directly to the target population of interest and determine if the recruited cohorts were representative. We do acknowledge that ideally this sample would have been recruited consecutively. A second limitation is the lack of detailed information on individual treatments received by patients in the cohort. The decision to not collect individual level treatment information was driven by the goal to develop tools that broadly predicted outcomes. There were also logistic hurdles that could not be overcome in attempting to consistently track individual level treatment information from clinics participating in different health systems. A final limitation to consider is the sample size. While the sample size was adequate for the primary study questions, it may be too small to complete subgroup analyses that go beyond our planned secondary analyses.

COLLABORATION

After completion of final follow-up, there will be an embargo on the data sharing to allow the investigator team to complete the primary and secondary analyses. It is anticipated that this embargo period will be no greater than 18 months after completion of the study. At that point, the data will be de-identified and freely available for download. The data will be hosted on the Orthopaedic Section of the American Physical Therapy Association website. There will be no restrictions to its use but to avoid duplicate reporting of findings permission from the Section must be gained by investigators who wish to reuse the data for scientific presentations or publications.

FURTHER DETAILS

Clinical Practice Guidelines from the Orthopaedic Section of the American Physical Therapy Association

have emphasised diagnosis, intervention and outcome assessment.⁴¹⁻⁴⁷ Screening and prognosis are relatively underdeveloped and data from this validation cohort will help to inform this physical therapy practice area. Analyses from the OSPRO validation cohort will add to this evidence base as it will be the first systematic investigation we are aware of that includes review of systems and yellow flag assessment by US physical therapists. Previous studies focusing on these processes have not combined review of systems with yellow flags and have been completed in primary care outside of USA.^{8, 48} The specificity of OSPRO may allow for direction suggestions to be made for improving clinical decision making in physical therapist practice in USA. Planned analyses from the already assembled validation cohort will assess the predictive capabilities of the OSPRO-YF and OSPRO-ROS tools for pain, function, quality of life, comorbidity change and healthcare utilisation outcomes. In future studies, we plan to expand on clinimetric properties of these tools by assessing reliability, respondent burden and comparisons to other established screening tools. Collectively, these planned and future analyses will evaluate the absolute and relative accuracy and efficiency of using the OSPRO tools to predict clinical and utilisation outcomes when compared with existing assessment paradigms.

Dissemination of the findings from the OSPRO validation will occur in several different venues. First, primary and secondary analyses will be published in peer-review journals that are accessible to physical therapists. Second, members of the investigator team will submit data from the validation cohort for presentation at scientific conferences. Third, the investigator team will plan educational sessions at national conferences that provide instruction on implementation of these tools. Fourth, a website hosted by the Orthopaedic Section is planned that allows for automated scoring of the tools and provides estimates of clinical outcomes. Finally, members of the investigator team will integrate findings from the OSPRO validation study during capacity building and community engagement opportunities with key musculoskeletal pain stakeholders.⁴⁹

Correction notice This paper has been amended since it was published Online First. Owing to a scripting error, some of the publisher names in the references were replaced with 'BMJ Publishing Group'. This only affected the full text version, not the PDF. We have since corrected these errors and the correct publishers have been inserted into the references.

Acknowledgements Brooks Rehabilitation provided resources for travel related to this study (e.g. clinic training and presentation of preliminary findings). OPT-IN Network Participants included: University of Florida: Joel Bialosky; UF Health: Giorgio Zeppieri, Jr., Daniel Broome, Marty Huegel, Debi Jones, Steve Emery, Mike Hodges, Derek Miles, Jodi Davis, Charlene Stubbington, Mike Darcy; ATI Physical Therapy: Ellen Shanley, Thomas Denninger, Jenna Bartsokas, Elise Harris, Jordan Floyd, Wade Harrell; University of Southern California: Lori Michener, Amy Pomrantz, Brooks Rehabilitation: Raine Osborne, Nata Salvatori, John Leschitz, Brian Hagist, Laura Langer, Tim Shreve, Nando Malaman, Michael Bourassa, Justin Zych, Tasha Mouton Shanklin; University of Illinois at Chicago: Aaron Keil, Brad Myers, Deb Davey, Justin Payette, Adam Wielechowski, Richard Severin, Erik Martinez; Indiana State University: Ryan Hanigan, Carolina Valencia, Danielle Jena, Nicole Woodard; Arcadia University: Angela Tate; Life's Work Physical Therapy: Sandra Stryker, Aaron Leonard, Erin Courtney, Brandon Little, Kathryn Jankord, Brad Simpson, Charleen

Hall, Paige Nixon, Julia Neufeld; University of Colorado, Denver: Paul Mintken, Virginia Arnette, Andrea Barsch.

Contributors SZG secured funding, provided overall design, gave input on the analysis plan and approved final version of the manuscript. JMB provided input on design and analysis plan and approved final version of the manuscript. TAL provided input on design, outcome measures and approved final version of the manuscript. SSW led the analysis plan and approved final version of the manuscript.

Funding All authors on this project were supported by the 2013 Clinical Research Network grant from the Orthopaedic Section, American Physical Therapy Association. SZG and JMB received additional support from Brooks Rehabilitation while designing this study and writing this protocol paper. JMB received support from the American National Institutes of Health (NIH) Rehabilitation Research Career Development Program (K12-HD055929). TAL received support from the Foundation for Physical Therapy with a Promotion of Doctoral Studies I (PODS I) Award.

Competing interests None declared.

Patient consent We used local IRB consent forms for this study.

Ethics approval University of Florida Institutional Review Board-01.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement This is not an original research article. There is a collaboration portion in the paper as is required for cohort profiles.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Pendergast J, Kliethermes SA, Freburger JK, *et al*. A comparison of health care use for physician-referred and self-referred episodes of outpatient physical therapy. *Health Serv Res* 2012;47:633-54.
- Mitchell JM, de Lissovoy G. A comparison of resource use and cost in direct access versus physician referral episodes of physical therapy. *Phys Ther* 1997;77:10-18.
- American Physical Therapy Association. Direct Access at the State Level. 2016 <http://www.apta.org/Statelssues/DirectAccess/>.
- Shoemaker MJ. Direct consumer access to physical therapy in Michigan: challenges to policy adoption. *Phys Ther* 2012;92:236-50.
- American Physical Therapy Association. Guide to Physical Therapist Practice 3.0. 2014 <http://guidetopractice.apta.org/>.
- Nicholas MK, Linton SJ, Watson PJ, *et al*. Psychological predictors of recovery from low back pain: a prospective study. *BMC Musculoskelet Disord* 2011;16.
- Main CJ, George SZ. Psychologically informed practice for management of low back pain: future directions in practice and research. *Phys Ther* 2011;91:820-4.
- Henschke N, Maher CG, Refshauge KM, *et al*. Prevalence of and screening for serious spinal pathology in patients presenting to primary care settings with acute low back pain. *Arthritis Rheum* 2009;60:3072-80.
- Underwood M. Diagnosing acute nonspecific low back pain: time to lower the red flags? *Arthritis Rheum* 2009;60:2855-7.
- Ferguson FC, Morison S, Ryan CG. Physiotherapists' understanding of red flags for back pain. *Musculoskeletal Care* 2015;13:42-50.
- Roach KE, Brown M, Ricker E, *et al*. The use of patient symptoms to screen for serious back problems. *J Orthop Sports Phys Ther* 1995;21:2-6.
- Foster NE, Delitto A. Embedding psychosocial perspectives within clinical management of low back pain: integration of psychosocially informed management principles into physical therapist practice--challenges and opportunities. *Phys Ther* 2011;91:790-803.
- Foster NE, Thomas E, Bishop A, *et al*. Distinctiveness of psychological obstacles to recovery in low back pain patients in primary care. *Pain* 2010;148:398-406.
- Singla M, Jones M, Edwards I, *et al*. Physiotherapists' assessment of patients' psychosocial status: are we standing on thin ice? A qualitative descriptive study. *Man Ther* 2015;20:328-34.

15. Perry JJ, Stiell IG. Impact of clinical decision rules on clinical care of traumatic injuries to the foot and ankle, knee, cervical spine, and head. *Injury* 2006;37:1157–65.
16. George SZ, Fritz JM, Bialosky JE, et al. The effect of a fear-avoidance-based physical therapy intervention for patients with acute low back pain: results of a randomized clinical trial. *Spine* 2003;28:2551–60.
17. George SZ, Zeppieri G, Cere AL, et al. A randomized trial of behavioral physical therapy interventions for acute and sub-acute low back pain (NCT00373867). *Pain* 2008;140:145–57.
18. Beneciuk JM, Bishop MD, Fritz JM, et al. The STarT Back Screening Tool and Individual Psychological Measures: Prognostic Indicator or Treatment Monitoring for Low Back Pain Clinical Outcomes. *Phys Ther* 2012;93:321–33.
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
20. Groll DL, To T, Bombardier C, et al. The development of a comorbidity index with physical function as the outcome. *J Clin Epidemiol* 2005;58:595–602.
21. George SZ, Beneciuk JM, Bialosky JE, et al. Development of a Review-of-Systems Screening Tool for Orthopaedic Physical Therapists: results from the optimal screening for prediction of referral and outcome (OSPRO) Cohort. *J Orthop Sports Phys Ther* 2015;45:512–26.
22. Lentz TA, Beneciuk JM, Bialosky JE, et al. Development of a yellow flag Assessment Tool for Orthopaedic Physical Therapists: results from the optimal screening for prediction of referral and outcome (OSPRO) Cohort. *J Orthop Sports Phys Ther* 2016;46:327–43.
23. Jensen MP, Turner JA, Romano JM, et al. Comparative reliability and validity of chronic pain intensity measures. *Pain* 1999;83:157–62.
24. Bolton JE. Accuracy of recall of usual pain intensity in back pain patients. *Pain* 1999;83:533–9.
25. Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. *Spine* 2005;30:1331–4.
26. Kosinski M, Dewey JE, et al. *How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8™*. Ware JEQuality Metric Incorporated, 2001.
27. Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. *J Manipulative Physiol Ther* 1991;14:409–15.
28. Vernon H. The Neck Disability Index: state-of-the-art, 1991–2008. *J Manipulative Physiol Ther* 2008;31:491–502.
29. Hudson-Cook N, Tomes-Nicholson K, Breen A. A revised Oswestry disability questionnaire. In: Roland MO, Jenner JR, eds. *Back Pain: New Approaches to Rehabilitation and Education*. New York, NY: Manchester University Press, 1989:187–204.
30. Fritz JM, Irrgang JJ. A comparison of a modified Oswestry Low Back Pain Disability Questionnaire and the Quebec Back Pain Disability Scale. *Phys Ther* 2001;81:776–88.
31. Beaton DE, Wright JG, Katz JN. Upper Extremity Collaborative G. Development of the QuickDASH: comparison of three item-reduction approaches. *J Bone Joint Surg Am* 2005;87:1038–46.
32. Irrgang JJ, Anderson AF, Boland AL, et al. Development and validation of the international knee documentation committee subjective knee form. *Am J Sports Med* 2001;29:600–13.
33. Freburger JK, Holmes GM, Agans RP, et al. The rising prevalence of chronic low back pain. *Arch Intern Med* 2009;169:251.
34. Carey TS, Freburger JK, Holmes GM, et al. Race, care seeking, and utilization for chronic back and neck pain: population perspectives. *J Pain* 2010;11.
35. Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH Task Force on research standards for chronic low back pain. *J Pain* 2014;15:569–85.
36. Daltroy LH, Cats-Baril WL, Katz JN, et al. The north american spine society lumbar spine outcome assessment Instrument: reliability and validity tests. *Spine* 1996;21:741–9.
37. George SZ, Robinson ME, Preference RME. Preference, expectation, and satisfaction in a clinical trial of behavioral interventions for acute and sub-acute low back pain. *J Pain* 2010;11:1074–82.
38. Steenstra IA, Ibrahim SA, Franche RL, et al. Validation of a risk factor-based intervention strategy model using data from the readiness for return to work cohort study. *J Occup Rehabil* 2010;20:394–405.
39. Brouwer S, Franche RL, Hogg-Johnson S, et al. Return-to-work self-efficacy: development and validation of a scale in claimants with musculoskeletal disorders. *J Occup Rehabil* 2011;21:244–58.
40. Traeger AC, Henschke N, Hübscher M, et al. Estimating the risk of chronic pain: development and Validation of a Prognostic Model (PICKUP) for patients with acute low back pain. *PLoS Med* 2016;13:e1002019.
41. McPoil TG, Martin RL, Cornwall MW, et al. Heel pain--plantar fasciitis: clinical practice guidelines linked to the international classification of function, disability, and health from the orthopaedic section of the American Physical Therapy Association. *J Orthop Sports Phys Ther* 2008;38:A1–A18.
42. Garcia CR, Martin RL, Houck J, et al. Orthopaedic Section of the American Physical Therapy A. Achilles pain, stiffness, and muscle power deficits: achilles tendinitis. *The Journal of orthopaedic and sports physical therapy* 2010 A1–A26.
43. Logerstedt DS, Snyder-Mackler L, Ritter RC, et al. Orthopaedic Section of the American Physical Therapist A. Knee stability and movement coordination impairments: knee ligament sprain. *The Journal of orthopaedic and sports physical therapy* 2010.
44. Logerstedt DS, Snyder-Mackler L, Ritter RC, et al. Orthopedic Section of the American Physical Therapy A. Knee pain and mobility impairments: meniscal and articular cartilage lesions. *The Journal of orthopaedic and sports physical therapy* 2010 40 A1–A35.
45. Cibulka MT, White DM, Woehle J, et al. Hip pain and mobility deficits--hip osteoarthritis: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association. *J Orthop Sports Phys Ther* 2009;39:A1–A25.
46. Childs JD, Cleland JA, Elliott JM, et al. American Physical Therapy Association. Neck pain: Clinical practice guidelines linked to the International Classification of Functioning, Disability, and Health from the Orthopedic Section of the American Physical Therapy Association. *J Orthop Sports Phys Ther* 2008;38.
47. Delitto A, George SZ, Van Dillen L, et al. Low Back Pain. *Journal of Orthopaedic & Sports Physical Therapy* 2012;42:A1–A57.
48. Hill JC, Dunn KM, Lewis M, et al. A primary care back pain screening tool: identifying patient subgroups for initial treatment. *Arthritis Rheum* 2008;59:632–41.
49. Patient-Centered Outcomes Research Institute. 'As a Matter of Pain' – Capacity Building & Community Engagement for Patient Centered Musculoskeletal Pain Research - Tier I. 2016 <http://www.pcori.org/research-results/2016/%E2%80%98-matter-pain%E2%80%99-%E2%80%93-capacity-building-community-engagement-patient-centered>.